Q-omics provides the consensus-scored CERS5 profile across patient tissues and cancer cell-line models. CERS5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CERS5 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CERS5 protein abundance shows 22,137 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where CERS5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CERS5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CERS5 survival associations across molecular data types. CERS5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CERS5 RNA expression–survival associations across cancer types. High CERS5 expression shows unfavorable associations in UVM, ACC, LIHC, MESO, KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CERS5 RNA expression.
This table summarizes CERS5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CERS5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CERS5 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, LUAD and READ. The HNSC box plot shows higher CERS5 RNA expression in tumor versus normal tissue (log2 FC = +1.058, t-test p < 0.001).
This table shows molecular features associated with CERS5 in patient tissues and cancer cell lines. In patient samples, CERS5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CERS5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
